Inventiva Announces Temporary Suspension of Its Stock Market Listing Ahead of a Financing Operation
The biopharmaceutical laboratory Inventiva has requested a temporary halt of its stock trading on Euronext Paris on Tuesday morning, ahead of a financing operation, the details of which will be communicated in an upcoming message.
A Defined Suspension Before a Financial Announcement
The suspension on the regulated market of Euronext Paris took effect from 9:00 AM CEST on Tuesday. Trading is expected to resume around 3:30 PM CEST, coinciding with the opening of trading in US dollars on the Nasdaq (9:30 AM ET), where the company is also listed under the same ticker 'IVA'. Inventiva has not specified the nature of the financing operation that led to this suspension. Detailed communication about this transaction is to occur as soon as possible, according to the company.
A Laboratory Focused on the Treatment of Steatohepatitis
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
Inventiva is a clinical-stage biotech specializing in the development of oral small molecules to treat steatohepatitis associated with metabolic dysfunction (MASH). The company is currently evaluating lanifibranor, a novel pan-PPAR agonist, in the phase 3 NATiV3 clinical trial aimed at adult patients suffering from this common, progressive chronic liver disease.
SectorSanté · Biotechnologies · Vaccins et laboratoires de recherche›Biotechnologie
Context
Period
Period: 1T2026
Key reported figures
Revenue: 0€
Risks mentioned
Aucune garantie que les bons de souscription seront exercés en totalité.
Inventiva a un historique d'exploitation limité et a subi des pertes importantes.
Opportunities identified
Estime que sa trésorerie lui permettra de financer ses activités jusqu'à la mi-premier trimestre 2027.
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
